Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 10Terminated 4Withdrawn 2Not yet recruiting 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Keratosis, Actinic 2Glioma 2Glioblastoma 2Brain Neoplasms 2Sarcoma 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × Aminolevulinic Acid × Clear all
NCT00977795 2019-09-10

A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors

Endeavor Health

Phase 1/2 Withdrawn
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01445691 2016-05-17

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Icahn School of Medicine at Mount Sinai

Phase 2 Withdrawn
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡